|
1）Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011; 96: 1587-609
|
|
|
|
2）Hazem A, Elamin MB, Bancos I, et al. Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. Eur J Endocrinol. 2012; 166: 13-20
|
|
|
|
|
|
3）Widdowson WM, Gibney J. The effect of growth hormone (GH) replacement on muscle strength in patients with GH-deficiency: a meta-analysis. Clin Endocrinol (Oxf). 2010; 72: 787-92
|
|
|
|
|
|
4）Widdowson WM, Gibney J. The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. J Clin Endocrinol Metab. 2008; 93: 4413-7
|
|
|
|
|
|
5）Elbornsson M, Gotherstrom G, Bosaeus I, et al. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol. 2012; 166: 787-95
|
|
|
|
|
|
6）Elbornsson M, Gotherstrom G, Bosaeus I, et al. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol. 2013; 168: 745-53
|
|
|
|
|
|
7）Appelman-Dijkstra NM, Claessen KMJA, Roelfsema F, et al. Therapy of Endocrine disease: Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. Eur J Endocrinol. 2013; 169: R1-14
|
|
|
|
|
|
8）Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010; 31: 301-42
|
|
|
|
|
|
9）van Bunderen CC, van Nieuwpoort IC, Arwert LI, et al. Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. J Clin Endocrinol Metab. 2011; 96: 3151-9
|
|
|
|
|
|
10）Gaillard RC, Mattsson AF, Akerblad AC, et al. Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol. 2012; 166: 1069-77
|
|
|
|
|
|
11）Burman P, Mattsson AF, Johannsson G, et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J Clin Endocrinol Metab. 2013; 98: 1466-75
|
|
|
|
|
|
12）Hartman ML, Xu R, Crowe BJ, et al. International HypoCCS Advisory Board. Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. J Clin Endocrinol Metab. 2013; 98: 980-8
|
|
|
|
|
|
13）Erfurth EA. Update in mortality in GH-treated patients. J Clin Endocrinol Metab. 2013; 98: 4219-26
|
|
|
|
|
|
14）Chihara K, Koledova E, Shimatsu A, et al. Adult growth hormone (GH) deficiency in Japanese patients: effects of GH treatment in a randomized, placebo-controlled trial. Eur J Endocrinol. 2004; 151: 343-50
|
|
|
|
|
|
15）Chihara K, Kato Y, Kohno H, et al. Efficacy and safety of growth hormone (GH) in the treatment of adult Japanese patients with GH deficiency: a randomized, placebo-controlled study. Growth Horm IGF Research. 2006; 16: 132-42
|
|
|
|
|
|
16）Chihara K, Kato Y, Takano K, et al. Effect of GH treatment on central fat accumulation in adult GH deficient Japanese patients: a randomized, placebo-controlled trial. Cur Med Res Opinion. 2006; 22: 1973-9
|
|
|
|
|
|
17）Chihara K, Kato Y, Shimatsu A, et al. Efficacy and safety of individualized growth hormone (GH) treatment in adult Japanese patients with GH deficiency. Growth Horm IGF Res. 2008; 18: 394-403
|
|
|
|
|
|
18）Chihara K, Fujieda K, Shimatsu A, et al. Dose-dependent changes in body composition during GH treatment in Japanese patients with adult growth hormone deficiency; A randomized, placebo-controlled trial. Growth Horm IGF Res. 2010; 20: 205-11
|
|
|
|
|
|
19）Shimatsu A, Tai S, Imori M, et al. Efficacy and safety of growth hormone replacement therapy in Japanese adults with growth hormone deficiency: a post-marketing observational study. Endocr J. 2013; 60: 1131-44
|
|
|
|